These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19803008)

  • 1. Treatment of complicated urinary tract infection caused by Pseudomonas aeruginosa--a comparison of the efficacy of ceftazidime with that of netilmicin.
    Graninger W; Ho I; Francesconi M; Schmidbauer C; Egger T
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():323-4. PubMed ID: 19803008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study on netilmicin in the treatment of complicated urinary tract infection caused by Pseudomonas aeruginosa].
    Murahashi I; Honda M; Maeda S; Takasaki E
    Jpn J Antibiot; 1982 Aug; 35(8):1919-24. PubMed ID: 6818388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ceftazidime in severe Gram-negative infections--a preliminary study.
    Clumeck N; Vanlaethem Y; Gordts B; Jaspar N; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():317-21. PubMed ID: 19803007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the usefulness of a novel injectable cephalosporin, E1040, and ceftazidime for management of complicated urinary tract infections caused by Pseudomonas aeruginosa and Proteus mirabilis by using the rat urolithiasis model.
    Satoh M; Munakata K; Takeuchi H; Yoshida O
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1580-3. PubMed ID: 1510458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early indicators of nephrotoxicity: comparison of two antibiotics.
    Cecconi M; Manfredi R; Cecarini L; Giorgi PL; Benedetti M; Accorroni V
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):452-7. PubMed ID: 3308720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. German Multicentre Study Group.
    Höffken G; Pasold R; Pflüger KH; Finke J; Fauser AA; Szelenyi H; Wagner J
    J Antimicrob Chemother; 1999 Sep; 44(3):367-76. PubMed ID: 10511404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime in patients with severe Pseudomonas infections.
    Lechi A; Arosio E; Montesi G; Vaona B; Ghidini O; Parrinello E
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):159-64. PubMed ID: 3516892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Netilmicin in urinary tract infections.
    Svare J; Johnsen NJ; Vesterhauge S; Lund F; Thomsen J; Vejlsgaard R
    Scand J Infect Dis Suppl; 1980; Suppl 23():132-4. PubMed ID: 6937957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous administration of ceftazidime as a salvage therapy in geriatrics: a case report.
    Michelon H; Tardivel M; Dinh A; Alvarez JC; Salomon E; Le Quintrec JL; Hirt D; Davido B
    Fundam Clin Pharmacol; 2020 Aug; 34(4):521-524. PubMed ID: 31709583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netilmicin in the treatment of Pseudomonas bacteremia.
    Lorber RR; Linzmayer MI
    Clin Ther; 1985; 7(3):338-46. PubMed ID: 3922616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro sensitivity of 39 strains of Pseudomonas aeruginosa isolated from urine culture of hospitalized patients].
    Vanni M; Zucca C
    Minerva Med; 1986 Jun; 77(27):1289-92. PubMed ID: 3088493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Netilmicin therapy of serious Gram-negative bacillary infections.
    Edelstein PH; Meyer RD
    J Antimicrob Chemother; 1978 Nov; 4(6):495-502. PubMed ID: 711647
    [No Abstract]   [Full Text] [Related]  

  • 14. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 15. Complicated urinary tract infection caused by Pseudomonas aeruginosa in a single institution (1999-2003).
    Shigemura K; Arakawa S; Sakai Y; Kinoshita S; Tanaka K; Fujisawa M
    Int J Urol; 2006 May; 13(5):538-42. PubMed ID: 16771722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and toxicity of netilmicin in the treatment of gram-negative infections.
    Buckwold FJ; Ronald AR; Lank B; Thompson L; Fox L; Harding GK
    Can Med Assoc J; 1979 Jan; 120(2):161-7. PubMed ID: 761144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime activity in experimental pseudomonas pyelonephritis in rats.
    Ritzerfeld W
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():257-9. PubMed ID: 19802995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Netilmicin sulfate as single-agent therapy for Pseudomonas infections.
    Greenberg RN; Hansbrough JN; Lorber RR; Miller GH
    South Med J; 1989 Jun; 82(6):715-8. PubMed ID: 2499934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
    Wagenlehner FM; Sobel JD; Newell P; Armstrong J; Huang X; Stone GG; Yates K; Gasink LB
    Clin Infect Dis; 2016 Sep; 63(6):754-762. PubMed ID: 27313268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of netilmicin and amikacin in treatment of complicated urinary tract infections.
    Maigaard S; Frimodt-Möller N; Madsen PO
    Antimicrob Agents Chemother; 1978 Oct; 14(4):544-8. PubMed ID: 363053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.